Ophthalmology Solution Articles & Analysis: Older
1 articles found
Aramis Biosciences announced that the first patient has been dosed in its phase 2 proof of concept clinical trial evaluating A197, a novel, first-in-class, topical immunomodulatory agent for the treatment of dry eye disease. “This is an important milestone for Aramis Biosciences and a hopeful moment for dry eye patients given the suboptimal efficacy and tolerability limitations commonly ...